The diabetic kidney disease sector is projected to reach $3.76 billion by 2030, driven by advancements in personalised medicine, early screening, and artificial intelligence, reshaping preventative care practices.
The diabetic kidney disease market is expected to keep expanding steadily through the end of the decade, according to The Business Research Company, which projects the sector will reach $3.76 billion by 2030. The report links that growth to better kidney-protective medicines, more frequent early screening, a heavier global burden of chronic kidney disease, and broader use of personalised treatment plans. It also says the market rose from $2.8 billion in 2025 to $2.96 billion in 2026, underscoring the pace of recent gains.
The company’s analysis points to a market shaped by long-standing clinical challenges as well as newer treatment practices. It says late diagnosis, limited early screening and reliance on dialysis in advanced cases have historically supported demand, while current growth is increasingly tied to efforts to slow progression before kidney damage becomes severe. The report highlights a growing role for multidisciplinary care, with hospitals, homecare providers and specialist centres all part of the treatment landscape.
Among the companies listed as active in the field are AstraZeneca, Pfizer, Novartis, Bayer, Sanofi, Bristol-Myers Squibb, Merck, Eli Lilly, Roche, Abbott and Boehringer Ingelheim, alongside a range of other drugmakers and diagnostics firms. The report cites AstraZeneca’s January 2023 acquisition of CinCor Pharma as an example of strategic deal-making, saying the move added baxdrostat, an experimental aldosterone synthase inhibitor aimed at resistant hypertension, to its cardiorenal pipeline.
Technology is also emerging as a central theme. The Business Research Company says artificial intelligence is increasingly being used to support prognostic tools that combine biomarker data with machine-learning models to estimate risk and guide earlier intervention. It points to Renalytix’s June 2023 FDA De Novo authorisation for KidneyIntelX.dkd, an AI-based platform for adults with type 2 diabetes and early-stage chronic kidney disease, as evidence that digital risk scoring is moving deeper into routine care. The report frames this as part of a wider shift towards more proactive management rather than treatment at a later stage.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
